TLR7 and cancer: Imiquimod (IMQ), a synthetic TLR7 agonist, has been reported to induce apoptosis via modulation of the expression of Bcl-2/Bax in cells of various cancer types, including renal cell carcinoma [7], intraepithelial neoplasia [8], squamous cell carcinoma [9] and basal cell carcinoma [10].